Hologic Inc

Hologic Inc(HOLX)股票分析

$76.010

+0.365 (+0.48%)收盘时

Loading chart…
最高
76.070
开盘
76.010
成交量加权均价
76.03
成交量
102.03M
市值
17.32B
最低
76.000
成交额
7.76B
企业价值/息税折旧摊销前利润(TTM)
11.25

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

AI 分析 of Hologic Inc (HOLX)

持有

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

分析师评级(19)

上行空间 +2.04%
买入
14 买入
5 持有
0 卖出
当前: 76.01
最低
76.00
平均
77.56
最高
79.00

Evercore ISI

2026-01-05

目标价

$78

In Line

BNP Paribas Exane

2025-11-21

目标价

$79

中性

Morgan Stanley

2025-11-10

目标价

$76

Equal Weight

Mizuho

2025-10-23

目标价

$78

中性

Stephens

2025-10-22

目标价

$76

Equal Weight

估值指标

Hologic Inc(HOLX)当前预期市盈率为 16.36,5 年平均预期市盈率为 18.07。

预期市盈率

合理
5 年均值 P/E
18.07
当前P/E
16.36
高估
21.06
低估
15.07

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
13.43
当前EV/EBITDA
11.25
高估
15.31
低估
11.56

预期市销率

低估
5 年均值 P/S
4.26
当前P/S
3.53
高估
4.79
低估
3.72

Alphio AI 对 HOLX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%HOLX

$90.01

情景价格

基

基准

基准 · 50%HOLX

$75.18

情景价格

悲

悲观

悲观 · 25%HOLX

$64.21

情景价格

持有 HOLX 的大户

T

Thematics Asset Management

+ 持有HOLX

+9.69%

3个月收益率

L

LMR Partners LLP

+ 持有HOLX

+6.53%

3个月收益率

M

Manulife Asset Management

+ 持有HOLX

+5.55%

3个月收益率

C

Capula Management Ltd

+ 持有HOLX

+5.00%

3个月收益率

C

Capstone Investment Advisors, LLC

+ 持有HOLX

+4.21%

3个月收益率

A

Argenta Asset Management SA

+ 持有HOLX

+3.53%

3个月收益率

事件时间线

2026-06-16 (ET)

13:30:00

Hologic Wins in Germany, Siemens Prohibited from Selling Mammography Systems

2026-04-07 (ET)

09:30:00

Hologic Completes Acquisition by Blackstone and TPG, Valued at Up to $79 per Share

2026-04-06 (ET)

17:20:00

Blackstone and TPG to Acquire Hologic, Deal Expected by April 7

17:20:00

Blackstone and TPG Acquire Hologic, Deal Expected by April 7

资讯

HOLX 常见问题 —— 由 Alphio AI 解答

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

19 analysts cover HOLX: 14 rate it Buy, 5 Hold and 0 Sell. The average price target is 77.56.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易